In:
Scientific Reports, Springer Science and Business Media LLC, Vol. 11, No. 1 ( 2021-01-19)
Abstract:
This study was conducted to investigate the impact of genetic variants of immune checkpoint genes on the treatment outcome in small cell lung cancer (SCLC). In the present study, 261 platinum doublet-treated SCLC patients were enrolled. A total of 96 polymorphisms in 33 immune checkpoint-related genes were selected, and their association with chemotherapy response and survival outcomes were analyzed. Among the polymorphisms studied, CD155 rs1058402G 〉 A (Ala67Thr, A67T) and CD226 rs763361C 〉 T (Gly307Ser, G307S) were significantly associated with SCLC treatment outcome. The rs1058402G 〉 A had a worse chemotherapy response and overall survival (under a dominant model, adjusted odds ratio [aOR] = 0.52, 95% confidence interval [CI] = 0.27–0.99, P = 0.05; adjusted hazard ratio [aHR] = 1.55, 95% CI = 1.12–2.14, P = 0.01, respectively). The rs763361C 〉 T had better chemotherapy response and overall survival (under a dominant model, aOR = 2.03, 95% CI = 1.10–3.75, P = 0.02; aHR = 0.69, 95% CI = 0.51–0.94, P = 0.02, respectively). When the rs1058402GA/AA and rs763361CC genotypes were combined, the chemotherapy response and overall survival were significantly decreased as the number of bad genotypes increased (aOR = 0.52, 95% CI = 0.33–0.81, P trend = 0.004; aHR = 1.48, 95% CI = 1.19–1.84, P trend = 4 × 10 −4 , respectively). The 3-D structural model showed that CD155 A67T created a new hydrogen bond and structural change on CD155 . These changes resulted in extending the distance and losing the hydrogen bonds between CD155 and CD226 , thus weakening CD155 / CD226 binding activity. In conclusion, CD155 rs1058402G 〉 A and CD226 rs763361C 〉 T may be useful for predicting the clinical outcomes of SCLC patients after chemotherapy.
Type of Medium:
Online Resource
ISSN:
2045-2322
DOI:
10.1038/s41598-021-81260-1
Language:
English
Publisher:
Springer Science and Business Media LLC
Publication Date:
2021
detail.hit.zdb_id:
2615211-3
